Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
Full description
PRIMARY OBJECTIVES:
I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity.
OUTLINE: This is an observational study.
Participants undergo blood sample collection and have their medical records reviewed on study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
* Adult (age ≥ 18 years at diagnosis)
Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m^2.
Exclusion criteria
* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
20 participants in 1 patient group
Loading...
Central trial contact
The Ohio State Comprehensive Cancer Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal